|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-1-4
|
|
pubmed:abstractText |
Ca2+/calmodulin-dependent protein kinase (CaMK) is an important downstream target of Ca2+ in the hypertrophic signaling pathways. We previously showed that the activation of apoptosis signal-regulating kinase 1 (ASK1) or NF-kappaB is sufficient for cardiomyocyte hypertrophy. Infection of isolated neonatal cardiomyocytes with an adenoviral vector expressing CaMKIIdelta3 (AdCaMKIIdelta3) induced the activation of ASK1, while KN93, an inhibitor of CaMKII, inhibited phenylephrine-induced ASK1 activation. Overexpression of CaMKIIdelta3 induced characteristic features of in vitro cardiomyocyte hypertrophy. Infection of cardiomyocytes with an adenoviral vector expressing a dominant negative mutant of ASK1 (AdASK(KM)) inhibited the CaMKIIdelta3-induced hypertrophic responses. Overexpression of CaMKIIdelta3 increased the kappaB-dependent promoter/luciferase activity and induced IkappaBalpha degradation. Coinfection with AdCaMKIIdelta3 and AdASK(KM), and pre-incubation with KN93 attenuated CaMKIIdelta3- and phenylephrine-induced NF-kappaB activation, respectively. Expression of a degradation resistant mutant of IkappaBalpha inhibited CaMKIIdelta3-induced hypertrophic responses. These results indicate that CaMKIIdelta3 induces cardiomyocyte hypertrophy mediated through ASK1-NF-kappaB signal transduction pathway.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0006-291X
|
|
pubmed:author |
pubmed-author:HiguchiYoshiharuY,
pubmed-author:HikosoShungoS,
pubmed-author:HirotaniShinichiS,
pubmed-author:HoriMasatsuguM,
pubmed-author:KashiwaseKazunoriK,
pubmed-author:MatsumuraYasushiY,
pubmed-author:NakaiAtsukoA,
pubmed-author:NishidaKazuhikoK,
pubmed-author:OtsuKinyaK,
pubmed-author:TakedaToshihiroT,
pubmed-author:TaniikeMasayukiM,
pubmed-author:TsujimotoIkukoI,
pubmed-author:UenoHikaruH,
pubmed-author:WatanabeTetsuyaT,
pubmed-author:YamaguchiOsamuO
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
327
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
136-42
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15629441-Animals,
pubmed-meshheading:15629441-Calcium,
pubmed-meshheading:15629441-Calcium-Calmodulin-Dependent Protein Kinase Type 2,
pubmed-meshheading:15629441-Calcium-Calmodulin-Dependent Protein Kinases,
pubmed-meshheading:15629441-Cardiomegaly,
pubmed-meshheading:15629441-Cells, Cultured,
pubmed-meshheading:15629441-Enzyme Activation,
pubmed-meshheading:15629441-Gene Expression Regulation,
pubmed-meshheading:15629441-Hydrogen Peroxide,
pubmed-meshheading:15629441-MAP Kinase Kinase Kinase 5,
pubmed-meshheading:15629441-Myocytes, Cardiac,
pubmed-meshheading:15629441-NF-kappa B,
pubmed-meshheading:15629441-Rats,
pubmed-meshheading:15629441-Rats, Wistar,
pubmed-meshheading:15629441-Signal Transduction
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
CaMKII activates ASK1 and NF-kappaB to induce cardiomyocyte hypertrophy.
|
|
pubmed:affiliation |
Department of Internal Medicine and Therapeutics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
